Investigational drugs under development for the treatment of PTSD.


INTRODUCTION:Posttraumatic stress disorder (PTSD) is a prevalent, chronic and disabling anxiety disorder that may develop following exposure to a traumatic event. There is currently no effective pharmacotherapy for PTSD and therefore the discovery of novel, evidence-based treatments is particularly important. This review of potential novel treatments could act as a catalyst for further drug investigation. AREAS COVERED:In this review, the authors discuss the heterogeneity of PTSD and why this provides a challenge for discovering effective treatments for this disorder. By searching for the neurobiological systems that are disrupted in individuals with PTSD and their correlation with different symptoms, the authors propose potential pharmacological treatments that could target these symptoms. They discuss drugs such as nabilone, d-cycloserine, nor-BNI, 7,8-dihydroxyflavone and oxytocin (OT) to target systems such as cannabinoids, glutamate, opioids, brain-derived neurotrophic factor and the OT receptor, respectively. While not conclusive, the authors believe that these brain systems include promising targets for drug discovery. Finally, the authors review animal studies, proof-of-concept studies and case studies that support our proposed treatments. EXPERT OPINION:A mechanism-based approach utilizing techniques such as in vivo neuroimaging will allow for the determination of treatments. Due to the heterogeneity of the PTSD phenotype, focusing on symptomology rather than a categorical diagnosis will allow for more personalized treatment. Furthermore, there appears to be a promise in drugs as cognitive enhancers, the use of drug cocktails and novel compounds that target specific pathways linked to the etiology of PTSD.


Ragen BJ,Seidel J,Chollak C,Pietrzak RH,Neumeister A




Has Abstract


2015-05-01 00:00:00












  • Toll-like receptor modulation in cardiovascular disease: a target for intervention?

    abstract::Toll-like receptors (TLRs) form a family of pattern recognition receptors that have emerged as key mediators of innate immunity. These receptors sense invading microbes and initiate the immune response. TLR-mediated inflammation is an important pathogenic link between innate immunity and a diverse panel of clinical di...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Földes G,von Haehling S,Anker SD

    更新日期:2006-08-01 00:00:00

  • Treatment of neurodegenerative diseases with neural cell transplantation.

    abstract::Neural cell transplantation is an emerging therapy that may provide an effective treatment for neurodegenerative disorders. The most extensive work with neural transplants has been carried out for Parkinson's and Huntington's diseases. However, intensive efforts are also being made for the treatment of other neurologi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Dinsmore JH

    更新日期:1998-04-01 00:00:00

  • Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy.

    abstract:INTRODUCTION:Studies in vitro and in vivo have identified several peptides that are potentially useful in treating systemic lupus erythematosus (SLE). The rationale for their use lies in the cost-effective production, high potency, target selectivity, low toxicity, and a peculiar mechanism of action that is mainly base...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Talotta R,Atzeni F,Laska MJ

    更新日期:2020-08-01 00:00:00

  • Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma.

    abstract:INTRODUCTION:Asthma is a chronic inflammatory disease characterized by bronchial hyper-reactivity. Although many currently available treatment regimens are effective, poor symptom control and refractory severe disease still represent major unmet needs. In the last years, numerous molecular therapeutic targets that inte...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Santus P,Radovanovic D

    更新日期:2016-09-01 00:00:00

  • Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil.

    abstract:BACKGROUND:Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs. OBJECTIVE:This review will examine a novel AAD, tedisamil--a multichannel potassium c...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Krishnamoorthy S,Lip GY

    更新日期:2009-08-01 00:00:00

  • AIT-082, a novel purine derivative with neuroregenerative properties.

    abstract::Preclinical and clinical evidence support the effectiveness of neurotrophins in Alzheimer's disease (AD) and neurodegenerative diseases. Delivery of neurotrophins to target sites in the brain remains a major obstacle for their use in humans. Development of orally active agents that mimic the effects of nerve growth fa...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Glasky AJ,Glasky MS,Ritzmann RF,Rathbone MP

    更新日期:1997-10-01 00:00:00

  • Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targete...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Vangapandu HV,Jain N,Gandhi V

    更新日期:2017-05-01 00:00:00

  • Investigational drugs for visceral leishmaniasis.

    abstract::Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed usin...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Sundar S,Chakravarty J

    更新日期:2015-01-01 00:00:00

  • Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.

    abstract:BACKGROUND:Based partially on encouraging findings from preclinical models, interest has grown in therapeutic inhibition of NF-kappaB to limit inflammatory injury during sepsis. However, NF-kappaB also regulates protective responses, and predicting the net survival effects of such inhibition may be difficult. OBJECTIV...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Li X,Su J,Cui X,Li Y,Barochia A,Eichacker PQ

    更新日期:2009-08-01 00:00:00

  • Targeting enzymes to cancers--new developments.

    abstract::Two methods of using tumour located enzymes have been described. These are antibody directed enzyme prodrug therapy (ADEPT) and macromolecule directed enzyme prodrug therapy (MDEPT), where the tumour located enzyme converts a non-toxic prodrug into a cytotoxic drug at tumour sites. The alternative use of tumour locate...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Bagshawe KD,Burke PJ,Knox RJ,Melton RG,Sharma SK

    更新日期:1999-02-01 00:00:00

  • Anti-adhesive strategies in the prevention of infectious disease at mucosal surfaces.

    abstract::Binding of microbial cell surface adhesins to host receptor molecules is a critical early step in microbial infection and pathogenesis. Anti-adhesive strategies aimed at blocking this interaction offer an attractive means of preventing infection at an early stage. The strategy should reduce the likelihood of resistant...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Kelly CG,Younson JS

    更新日期:2000-08-01 00:00:00

  • Current drugs and medical treatment algorithms in the management of acute decompensated heart failure.

    abstract:BACKGROUND:Acute decompensated heart failure (ADHF) is associated with increased hospitalization rates and high in-hospital mortality, and has emerged as a major public health problem over the past decade. In recent years, several new drugs and therapeutic approaches have failed to reduce short- and long-term morbidity...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Triposkiadis F,Parissis JT,Starling RC,Skoularigis J,Louridas G

    更新日期:2009-06-01 00:00:00

  • A perspective on RNA interference-based therapeutics for metabolic liver diseases.

    abstract::Introduction: Therapeutic oligonucleotides have emerged as a promising new class of drug that could silence undruggable targets; they can potentially treat metabolic liver diseases such as nonalcoholic fatty liver disease (NAFLD), hereditary hemochromatosis and alpha 1 antitrypsin deficiency. Areas covered: This artic...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Alkhouri N,Gawrieh S

    更新日期:2021-01-29 00:00:00

  • Insulin aspart: a novel rapid-acting human insulin analogue.

    abstract::In order to improve therapy and increase the quality of life for diabetic patients, it has been of significant interest to develop rapid-acting insulin preparations that mimic the physiological meal-time profile of insulin more closely than soluble human insulin. Insulin aspart (B28Asp human insulin) is a novel rapid-...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Gammeltoft S,Hansen BF,Dideriksen L,Lindholm A,Schäffer L,Trüb T,Dayan A,Kurtzhals P

    更新日期:1999-09-01 00:00:00

  • Immunotherapy in atopic dermatitis.

    abstract::Atopic dermatitis (AD) is a common inflammatory disease involving the skin and often other organs and systems, mainly respiratory. A definitive general consensus on the AD pathogenesis has not yet been established, however several lines of evidence suggest that T-cells play a crucial role in priming AD early-stage les...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Mastrandrea F

    更新日期:2001-01-01 00:00:00

  • Lebrikizumab for the treatment of asthma.

    abstract:INTRODUCTION:In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Antoniu SA

    更新日期:2016-10-01 00:00:00

  • Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases.

    abstract::Prinomastat (formerly AG3340, Agouron Pharmaceuticals, Inc.) is a potent, selective oral inhibitor of matrix metalloproteinase-2, -9, -13 and -14. This peculiar selectivity should represent an advantage for prinomastat in terms of efficacy/tolerability. The drug has been shown to inhibit tumour growth and angiogenesis...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Scatena R

    更新日期:2000-09-01 00:00:00

  • The therapeutic potential of PD156707 and related butenolide endothelin antagonists.

    abstract::Plasma concentrations of the peptide endothelin (ET) are elevated in several cardiovascular diseases. Animal studies suggest that activation of ET receptors may contribute to the increase in vascular resistance and remodelling of cardiovascular tissues that are characteristic of these pathologies. Antagonists of these...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Maguire JJ,Davenport AP

    更新日期:1999-01-01 00:00:00

  • PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.

    abstract:INTRODUCTION:Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blockin...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Allocca M,Gilardi D,Fiorino G,Furfaro F,Argollo M,Peyrin-Biroulet L,Danese S

    更新日期:2018-07-01 00:00:00

  • Beclabuvir for the treatment of hepatitis C.

    abstract:INTRODUCTION:About 185,000,000 people worldwide are chronically infected with hepatitis C virus (HCV). Currently, the most successful HCV infection antiviral therapies reduce the chance of progression towards the advanced phases of the hepatopathy (liver cirrhosis, hepatocellular carcinoma and death). Recently, however...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Gentile I,Zappulo E,Buonomo AR,Maraolo AE,Borgia G

    更新日期:2015-01-01 00:00:00

  • Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.

    abstract::There is a growing understanding of the central role that platelets play in coronary artery disease. The glycoprotein IIb/IIIa receptor has recently been identified as the final common pathway for platelet aggregation and hence has been the focus of many clinical trials to influence various aspects of coronary artery ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Salam AM,Suwaidi JA

    更新日期:2002-11-01 00:00:00

  • Anti-epidermal growth factor receptor drugs in cancer therapy.

    abstract::The epidermal growth factor receptor is a cell membrane growth factor receptor that plays a key role in cancer development and progression. Epidermal growth factor receptor-activated signalling pathways control cell proliferation, apoptosis, angiogenesis and metastatic spread in the majority of human epithelial cancer...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Ciardiello F,Tortora G

    更新日期:2002-06-01 00:00:00

  • Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy.

    abstract::PDE3 cyclic nucleotide phosphodiesterases are important in cyclic AMP (cAMP) and possibly cyclic GMP-mediated signalling in cardiac and vascular smooth muscle myocytes. Drugs that inhibit these enzymes have inotropic and vasodilatory actions that have proven useful in the short-term treatment of contractile failure an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Movsesian MA,Alharethi R

    更新日期:2002-11-01 00:00:00

  • A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule.

    abstract::Helicobacter pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: de Boer WA

    更新日期:2001-08-01 00:00:00

  • Novel agents for the treatment of polycythemia vera: an insight into preclinical research and early phase clinical trials.

    abstract:INTRODUCTION:Current treatment for polycythemia vera (PV) is limited and primarily targets thrombosis risk. Agents targeting distinct mechanisms of action within myeloproliferation are undergoing clinical evaluation to optimize efficacy, improve tolerance and augment long term disease complications. AREA COVERED:This ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Padrnos L,Mesa R

    更新日期:2020-08-01 00:00:00

  • Discontinued drugs in 2008: oncology drugs.

    abstract::The failure of drug candidates in clinical development remains a critical issue for the pharmaceutical and biotechnology industries. This article documents those oncology drugs discontinued in 2008 and briefly reviews reasons for termination of development. Source information was derived from a search of the Pharmapro...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章


    authors: Williams R

    更新日期:2009-11-01 00:00:00

  • Therapeutic potential of S179D prolactin--from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator.

    abstract::Increasing evidence suggests an important role for autocrine/paracrine prolactin in breast and prostate cancers and other disease states. Prolactin production in these extrapituitary sites is not governed by dopamine agonists, a finding that has spurred the production of prolactin receptor antagonists. This review foc...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Walker AM

    更新日期:2006-10-01 00:00:00

  • Transcription therapy for acute promyelocytic leukaemia.

    abstract::Transcription factors are proteins that regulate gene transcription and expression. In many cases of acute leukaemia chromosomal aberrations are translocations of transcription factors which change their expression and induce the leukaemic phenotype. These abnormal transcription factors are tumour-specific and can be ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Douer D

    更新日期:2000-02-01 00:00:00

  • Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis.

    abstract::Diminished efficacy in terms of clinical relapses and lesion load on magnetic resonance images for patients developing neutralising antibodies (NAbs) to recombinant IFN-beta may be found in multiple sclerosis. NAbs become detectable over the first few years of therapy, disappearing during the treatment course in some ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Bagnato F,Pozzilli C

    更新日期:2003-07-01 00:00:00

  • Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.

    abstract::The tremendous increase in the global prevalence of Type 2 diabetes (T2D) and its conglomeration of metabolic disorders has dramatically intensified the search for innovative therapies to fight this emerging epidemic. Over the last decade, the family of nuclear receptors, especially the peroxisome proliferator-activat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审


    authors: Savkur RS,Miller AR

    更新日期:2006-07-01 00:00:00